NMPA Approves Marketing Update for Baiyunshan's Drug Products
China’s NMPA approves marketing update for Baiyunshan's Pseudoephedrine Granules and Paracetamol.
The National Medical Products Administration has approved a
supplementary medication application for Guangxi Baiyunshan Yingkang
Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Baiyunshan Pharmaceutical
Holdings Company. The permission relates to a modification in the topic of the
drug marketing authorisation for their product, Pseudoephedrine Granules and
Compound Paracetamol. The company's product portfolio is taking a significant
stride forward with this regulatory milestone.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
More from Pharma News
All stories →
IDEAYA Biosciences Achieves 17.4-Month Median OS with IDE849 ADC in Relapsed SCLC
FDA Issues Twelve Biologics Guidance Documents Covering Container Closure, Blood Manufacturing, and Biosimilars
Discussion